← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-04-23 08:00:00 | New Pearson Research: The New Ai Talent Strategy Is Redesigning Roles Along with the importance of global reskilling, new pearson research shows age of ai calls for employers to focus on creative strategies to close talent gaps in their workforce london , april 23, 2025 /prnewswire/ -- new research from pearson (ftse: pson.l), the world’s lifelong learning company, shows that, as roles in the technology industry are being reshaped by automation and ai, employers should consider a strategy of ’role redesign’ to solve talent needs and maintain competitiveness. for this latest skills outlook, solving the tech talent gap from within, pearson looked at how the tech workforce might evolve and be reshaped by emerging technology over the next five years. |
2025-04-09 12:00:00 | Certifications Fuel Success In The Age Of Ai: Pearson Releases The 2025 Value Of It Certification Candidate Report San diego , april 9, 2025 /prnewswire/ -- pearson (ftse: pson.l) and its pearson vue business, the global leader in computer-based testing, released their newest value of it certification candidate report. this comprehensive study, the ninth in an ongoing series, provides crucial insights into the evolving landscape of it certification and its impact on professionals and organizations worldwide. |
2025-04-07 10:00:00 | Pearson Redefines Its Brand To Embrace The Future Of Learning New brand identity reflects learning as a core human need, essential for personal happiness and progress london , april 7, 2025 /prnewswire/ -- pearson (ftse: pson.l), the world’s leading learning company, today unveiled a dynamic new brand identity that demonstrates its leadership as a lifelong learning company. more than just a refreshed logo, the rebrand represents a deep understanding of the evolving needs of learners worldwide. |
2025-04-03 07:16:00 | Minovia Therapeutics Announces Fda Clearance Of Second Ind Application, For A Phase Ii Clinical Trial Of Lead Product Mnv-201 In Pearson Syndrome Mnv-201 is minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria rare pediatr i c designation granted mnv-201 is also being studied in a phase ib for low-risk myelodysplastic syndrome; preliminary clinical data demonstrate safety and efficacy haifa, israel, april 03, 2025 (globe newswire) -- minovia therapeutics ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the u.s. food and drug administration (fda) has cleared its second investigational new drug (ind) application for mnv-201 , an autologous hematopoietic stem cell product augmented with allogeneic mitochondria . the ind supports the initiation of a phase i i clinical trial of mnv-201 in pediatric patients with pearson syndrome, a primary mitochondrial disease. |
2025-04-01 09:30:00 | Extensishr’s David R. Pearson Honored As Chro Of The Year By C-suite Insider Woodbridge, n.j.--(business wire)-- #hr--extensishr’s david r. pearson has been named “chro of the year (peo & hro) – new jersey 2025” by c-suite insider. |
2025-03-31 12:00:00 |
|
2025-03-31 08:00:00 |
|
2025-03-07 09:01:00 |
|
2025-02-28 05:00:00 |
|
2025-02-28 02:15:00 |
|
2025-02-28 02:10:00 |
|
2025-01-22 12:03:00 |
|
2025-01-16 02:15:00 |
|
2025-01-14 11:00:00 |
|
2025-01-09 06:03:00 |
|

📰 Browse additional press releases for Pearson!
Sign up for free or log in✍️ Sign up to get "The Checklist Value Investor — A Smarter Way to Pick Stocks" for free